Highest-materiality recent filing
Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Lee and Martin
James Sapirstein appointed CEO effective June 3, 2026; prior CEO of Entero Therapeutics (Nasdaq: ENTO).
Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin
James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988
FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988
First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates
Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage
Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.
Cocrystal Pharma announces up to $13M registered direct offering at $1.70/share
$4.7M upfront from sale of 2,764,710 shares at $1.70; closing expected Sep 15, 2025.
CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances
Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable
No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones
Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set
Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor
CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024
In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A
Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A
Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.
CDI-988 (pan-norovirus/coronavirus 3CL protease inhibitor) Phase 1 in Australia shows favorable safety in single-ascending dose cohorts.
Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.
the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately
On April 20, 2023, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) appointed Fred Hassan as a director, thereby increasing the number of directors to six.
Max materiality 0.75 · Median 0.55 · Most common event other_material